Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $155
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $144 to $155.
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $144 to $155.